i
Interim estimates of vaccine effectiveness of Pfizer-BioNTech and Moderna Covid-19 Vaccines among health care personnel — 33 U.S. sites, January–March 2021
-
May 14, 2021
Details:
-
Personal Author:
-
Corporate Authors:
-
Description:What is already known about this topic? Health care personnel (HCP) are at high risk for COVID-19. The early distribution of two mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna) to HCP provided an opportunity to examine vaccine effectiveness in a real-world setting.
What is added by this report? The first U.S. multisite test-negative design vaccine effectiveness study among HCP found a single dose of Pfizer-BioNTech or Moderna Covid-19 Vaccines to be 82% effective against symptomatic COVID-19 and 2 doses to be 94% effective.
What are the implications for public health practice? The mRNA vaccines are highly effective at preventing symptomatic COVID-19 among U.S. HCP. High vaccination coverage among HCP and the general population is critical to prevent COVID-19 in the United Statesmm7020e2.htm?s_cid=mm7020e2_w
mm7020e2-H.pdf
-
Subjects:
-
Series:
-
Document Type:
-
Name as Subject:
-
Place as Subject:
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type: